Xingnaojing for Moderate-to-severe Acute ischemic Stroke (XMAS): study protocol for a randomized controlled trial

DiscussionThe results of this trial will provide critical evidence for XNJ in the treatment of AIS as a complementary approach that can be initiated after reperfusion therapy or when the AIS is not eligible for thrombolytic treatment.Trial registrationClinical Trials.gov, ID:NCT02728180. Registered on 28 March 2016.
Source: Trials - Category: Research Source Type: clinical trials